Sanofi flagged a second delay to an FDA decision for its experimental multiple sclerosis drug and reported disappointing ...
Dupixent For Moderate-To-Severe Asthma Treatment Market Expected To Reach ~$8.1 Billion By 2032. December 13, 2025 7:27 am - The Dupixent market for moderate-to-severe asthma is valued at $3.25 ...
Kymera drug positioned to rival Sanofi and Regeneron’s Dupixent succeeds in early-stage eczema trial
Now, the company will aim to show the drug helps patients with eczema and asthma in larger, placebo-controlled trial.
This year has been one for the books in medicine. From Ozempic’s expanded role in protecting failing kidneys to long‑acting ...
In 2025, drug approvals widen treatment options for chronic diseases, infections and pain, including Ozempic kidney ...
So, Regeneron's revenue rose 1.9% from $3.68 billion in Q2 2025 to $3.75 billion, beating consensus estimate by $160 million ...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is included among the 14 Best US Stocks to Buy for Long Term. On December 4, ...
RegRegon Pharmaceuticals and Sanofi recently announced that the European Commission approved Dupixent for treating moderate-to-severe chronic spontaneous urticaria in patients aged 12 and above who do ...
In the EU, there are approximately 270,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite standard-of-care antihistamine treatment Dupixent, which ...
Investor's Business Daily on MSN
Kymera rockets, pulling Nurix higher. Does it have the next Dupixent?
Kymera Therapeutics could have the next Dupixent, analysts said Monday, as shares skyrocketed on promising test results in ...
After a series of unfortunate regulatory rejections and manufacturing issues surfaced, Regeneron’s shares dipped to $483 this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback